Search

Your search keyword '"Ingle, James N."' showing total 1,241 results
Start Over Author "Ingle, James N."

Refine your results

more »

more »

more »

more »
1,241 results on '"Ingle, James N."'

2. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer

Author

Leon-Ferre, Roberto A., Whitaker, Kaitlyn R., Suman, Vera J., Hoskin, Tanya, Giridhar, Karthik V., Moore, Raymond M., Al-Jarrad, Ahmad, McLaughlin, Sarah A., Northfelt, Donald W., Hunt, Katie N., Conners, Amy Lynn, Moyer, Ann, Carter, Jodi M., Kalari, Krishna, Weinshilboum, Richard, Wang, Liewei, Ingle, James N., Knutson, Keith L., Ansell, Stephen M., Boughey, Judy C., Goetz, Matthew P., and Villasboas, Jose C.

Published
2024
Full Text
View/download PDF

5. Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

Author

Jayaraman, Swaathi, Wu, Xinyan, Kalari, Krishna R., Tang, Xiaojia, Kuffel, Mary J., Bruinsma, Elizabeth S., Jalali, Shahrzad, Peterson, Kevin L., Correia, Cristina, Kudgus, Rachel A., Kaufmann, Scott H., Renuse, Santosh, Ingle, James N., Reid, Joel M., Ames, Matthew M., Fields, Alan P., Schellenberg, Matthew J., Hawse, John R., Pandey, Akhilesh, and Goetz, Matthew P.

Published
2023
Full Text
View/download PDF

6. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

Author

Carter, Jodi M., Chumsri, Saranya, Hinerfeld, Douglas A., Ma, Yaohua, Wang, Xue, Zahrieh, David, Hillman, David W., Tenner, Kathleen S., Kachergus, Jennifer M., Brauer, Heather Ann, Warren, Sarah E., Henderson, David, Shi, Ji, Liu, Yi, Joensuu, Heikki, Lindman, Henrik, Leon-Ferre, Roberto A., Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna R., Couch, Fergus J., Knutson, Keith L., Goetz, Matthew P., Perez, Edith A., and Thompson, E. Aubrey

Published
2023
Full Text
View/download PDF

8. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer

Author

Aspros, Kirsten G. M., Carter, Jodi M., Hoskin, Tanya L., Suman, Vera J., Subramaniam, Malayannan, Emch, Michael J., Ye, Zhenqing, Sun, Zhifu, Sinnwell, Jason P., Thompson, Kevin J., Tang, Xiaojia, Rodman, Esther P. B., Wang, Xiyin, Nelson, Adam W., Chernukhin, Igor, Hamdan, Feda H., Bruinsma, Elizabeth S., Carroll, Jason S., Fernandez-Zapico, Martin E., Johnsen, Steven A., Kalari, Krishna R., Huang, Haojie, Leon-Ferre, Roberto A., Couch, Fergus J., Ingle, James N., Goetz, Matthew P., and Hawse, John R.

Published
2022
Full Text
View/download PDF

11. Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.

Author

Chapman, Judith-Anne W., Bayani, Jane, SenGupta, Sandip, Bartlett, John M.S., Piper, Tammy, Quintayo, Mary Anne, Virk, Shakeel, Goss, Paul E., Ingle, James N., Ellis, Matthew J., Sledge, George W., Budd, G. Thomas, Rabaglio, Manuela, Ansari, Rafat H., Tozer, Richard, D'Souza, David P., Chalchal, Haji, Spadafora, Silvana, Stearns, Vered, and Perez, Edith A.

Published
2024
Full Text
View/download PDF

12. Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

Author

Jalalirad, Mohammad, Haddad, Tufia C., Salisbury, Jeffrey L., Radisky, Derek, Zhang, Minzhi, Schroeder, Mark, Tuma, Ann, Leof, Eduard, Carter, Jodi M., Degnim, Amy C., Boughey, Judy C., Sarkaria, Jann, Yu, Jia, Wang, Liewei, Liu, Minetta C., Zammataro, Luca, Malatino, Lorenzo, Galanis, Evanthia, Ingle, James N., Goetz, Matthew P., and D’Assoro, Antonino B.

Published
2021
Full Text
View/download PDF

13. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer

Author

Polley, Mei-Yin C., Leon-Ferre, Roberto A., Leung, Samuel, Cheng, Angela, Gao, Dongxia, Sinnwell, Jason, Liu, Heshan, Hillman, David W., Eyman-Casey, Abraham, Gilbert, Judith A., Negron, Vivian, Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna, Couch, Fergus, Carter, Jodi M., Visscher, Daniel W., Nielsen, Torsten O., and Goetz, Matthew P.

Published
2021
Full Text
View/download PDF

14. Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Author

Yu, Jia, Qin, Bo, Moyer, Ann M., Sinnwell, Jason P., Thompson, Kevin J., Copland, III, John A., Marlow, Laura A., Miller, James L., Yin, Ping, Gao, Bowen, Minter-Dykhouse, Katherine, Tang, Xiaojia, McLaughlin, Sarah A., Moreno-Aspitia, Alvaro, Schweitzer, Anthony, Lu, Yan, Hubbard, Jason, Northfelt, Donald W., Gray, Richard J., Hunt, Katie, Conners, Amy L., Suman, Vera J., Kalari, Krishna R., Ingle, James N., Lou, Zhenkun, Visscher, Daniel W., Weinshilboum, Richard, Boughey, Judy C., Goetz, Matthew P., and Wang, Liewei

Published
2021
Full Text
View/download PDF

15. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer

Author

O’Regan, Ruth M., Zhang, Yi, Fleming, Gini F., Francis, Prudence A., Kammler, Roswitha, Viale, Giuseppe, Dell’Orto, Patrizia, Lang, Istvan, Bellet, Meritxell, Bonnefoi, Herve R., Tondini, Carlo, Villa, Federica, Bernardo, Antonio, Ciruelos, Eva M., Neven, Patrick, Karlsson, Per, Müller, Bettina, Jochum, Wolfram, Zaman, Khalil, Martino, Silvana, Geyer, Charles E., Jerzak, Katarzyna J., Davidson, Nancy E., Coleman, Robert E., Ingle, James N., van Mackelenbergh, Marion T., Loi, Sherene, Colleoni, Marco, Schnabel, Catherine A., Treuner, Kai, and Regan, Meredith M.

Abstract

IMPORTANCE: Adjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor–positive (HR+) breast cancer but adds adverse effects. A genomic biomarker for selecting patients most likely to benefit from OFS-based treatment is lacking. OBJECTIVE: To assess the predictive and prognostic performance of the Breast Cancer Index (BCI) for OFS benefit in premenopausal women with HR+ breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This prospective-retrospective translational study used all available tumor tissue samples from female patients from the Suppression of Ovarian Function Trial (SOFT). These individuals were randomized to receive 5 years of adjuvant tamoxifen alone, tamoxifen plus OFS, or exemestane plus OFS. BCI testing was performed blinded to clinical data and outcome. The a priori hypothesis was that BCI HOXB13/IL17BR ratio (BCI[H/I])–high tumors would benefit more from OFS and high BCI portended poorer prognosis in this population. Settings spanned multiple centers internationally. Participants included premenopausal female patients with HR+ early breast cancer with specimens in the International Breast Cancer Study Group tumor repository available for RNA extraction. Data were collected from December 2003 to April 2021 and were analyzed from May 2022 to October 2022. MAIN OUTCOMES AND MEASURES: Primary end points were breast cancer–free interval (BCFI) for the predictive analysis and distant recurrence-free interval (DRFI) for the prognostic analyses. RESULTS: Tumor specimens were available for 1718 of the 3047 female patients in the SOFT intention-to-treat population. The 1687 patients (98.2%) who had specimens that yielded sufficient RNA for BCI testing represented the parent trial population. The median (IQR) follow-up time was 12 (10.5-13.4) years, and 512 patients (30.3%) were younger than 40 years. Tumors were BCI(H/I)-low for 972 patients (57.6%) and BCI(H/I)-high for 715 patients (42.4%). Patients with tumors classified as BCI(H/I)-low exhibited a 12-year absolute benefit in BCFI of 11.6% from exemestane plus OFS (hazard ratio [HR], 0.48 [95% CI, 0.33-0.71]) and an absolute benefit of 7.3% from tamoxifen plus OFS (HR, 0.69 [95% CI, 0.48-0.97]) relative to tamoxifen alone. In contrast, patients with BCI(H/I)-high tumors did not benefit from either exemestane plus OFS (absolute benefit, −0.4%; HR, 1.03 [95% CI, 0.70-1.53]; P for interaction = .006) or tamoxifen plus OFS (absolute benefit, −1.2%; HR, 1.05 [95% CI, 0.72-1.54]; P for interaction = .11) compared with tamoxifen alone. BCI continuous index was significantly prognostic in the N0 subgroup for DRFI (n = 1110; P = .004), with 12-year DRFI of 95.9%, 90.8%, and 86.3% in BCI low-risk, intermediate-risk, and high-risk N0 cancers, respectively. CONCLUSIONS AND RELEVANCE: In this prospective-retrospective translational study of patients enrolled in SOFT, BCI was confirmed as prognostic in premenopausal women with HR+ breast cancer. The benefit from OFS-containing adjuvant endocrine therapy was greater for patients with BCI(H/I)-low tumors than BCI(H/I)-high tumors. BCI(H/I)-low status may identify premenopausal patients who are likely to benefit from this more intensive endocrine therapy.

Published
2024
Full Text
View/download PDF

16. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Author

Purrington, Kristen S, Slager, Susan, Eccles, Diana, Yannoukakos, Drakoulis, Fasching, Peter A, Miron, Penelope, Carpenter, Jane, Chang-Claude, Jenny, Martin, Nicholas G, Montgomery, Grant W, Kristensen, Vessela, Anton-Culver, Hoda, Goodfellow, Paul, Tapper, William J, Rafiq, Sajjad, Gerty, Susan M, Durcan, Lorraine, Konstantopoulou, Irene, Fostira, Florentia, Vratimos, Athanassios, Apostolou, Paraskevi, Konstanta, Irene, Kotoula, Vassiliki, Lakis, Sotiris, Dimopoulos, Meletios A, Skarlos, Dimosthenis, Pectasides, Dimitrios, Fountzilas, George, Beckmann, Matthias W, Hein, Alexander, Ruebner, Matthias, Ekici, Arif B, Hartmann, Arndt, Schulz-Wendtland, Ruediger, Renner, Stefan P, Janni, Wolfgang, Rack, Brigitte, Scholz, Christoph, Neugebauer, Julia, Andergassen, Ulrich, Lux, Michael P, Haeberle, Lothar, Clarke, Christine, Pathmanathan, Nirmala, Rudolph, Anja, Flesch-Janys, Dieter, Nickels, Stefan, Olson, Janet E, Ingle, James N, Olswold, Curtis, Slettedahl, Seth, Eckel-Passow, Jeanette E, Anderson, S Keith, Visscher, Daniel W, Cafourek, Victoria L, Sicotte, Hugues, Prodduturi, Naresh, Weiderpass, Elisabete, Bernstein, Leslie, Ziogas, Argyrios, Ivanovich, Jennifer, Giles, Graham G, Baglietto, Laura, Southey, Melissa, Kosma, Veli-Matti, Fischer, Hans-Peter, GENICA Network, Reed, Malcom WR, Cross, Simon S, Deming-Halverson, Sandra, Shrubsole, Martha, Cai, Qiuyin, Shu, Xiao-Ou, Daly, Mary, Weaver, Joellen, Ross, Eric, Klemp, Jennifer, Sharma, Priyanka, Torres, Diana, Rüdiger, Thomas, Wölfing, Heidrun, Ulmer, Hans-Ulrich, Försti, Asta, Khoury, Thaer, Kumar, Shicha, Pilarski, Robert, Shapiro, Charles L, Greco, Dario, Heikkilä, Päivi, Aittomäki, Kristiina, Blomqvist, Carl, Irwanto, Astrid, Liu, Jianjun, Pankratz, Vernon Shane, Wang, Xianshu, Severi, Gianluca, Mannermaa, Arto, Easton, Douglas, Hall, Per, and Brauch, Hiltrud

Subjects
GENICA Network, Chromosomes, Human, Pair 19, Humans, Genetic Predisposition to Disease, Estrogen Receptor alpha, Case-Control Studies, Polymorphism, Single Nucleotide, Quantitative Trait Loci, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Genome-Wide Association Study, Young Adult, Triple Negative Breast Neoplasms, Prevention, Genetics, Cancer, Breast Cancer, Clinical Research, Human Genome, 2.1 Biological and endogenous factors, Chromosomes, Human, Pair 19, Polymorphism, Single Nucleotide, and over, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Triple-negative (TN) breast cancer is an aggressive subtype of breast cancer associated with a unique set of epidemiologic and genetic risk factors. We conducted a two-stage genome-wide association study of TN breast cancer (stage 1: 1529 TN cases, 3399 controls; stage 2: 2148 cases, 1309 controls) to identify loci that influence TN breast cancer risk. Variants in the 19p13.1 and PTHLH loci showed genome-wide significant associations (P < 5 × 10(-) (8)) in stage 1 and 2 combined. Results also suggested a substantial enrichment of significantly associated variants among the single nucleotide polymorphisms (SNPs) analyzed in stage 2. Variants from 25 of 74 known breast cancer susceptibility loci were also associated with risk of TN breast cancer (P < 0.05). Associations with TN breast cancer were confirmed for 10 loci (LGR6, MDM4, CASP8, 2q35, 2p24.1, TERT-rs10069690, ESR1, TOX3, 19p13.1, RALY), and we identified associations with TN breast cancer for 15 additional breast cancer loci (P < 0.05: PEX14, 2q24.1, 2q31.1, ADAM29, EBF1, TCF7L2, 11q13.1, 11q24.3, 12p13.1, PTHLH, NTN4, 12q24, BRCA2, RAD51L1-rs2588809, MKL1). Further, two SNPs independent of previously reported signals in ESR1 [rs12525163 odds ratio (OR) = 1.15, P = 4.9 × 10(-) (4)] and 19p13.1 (rs1864112 OR = 0.84, P = 1.8 × 10(-) (9)) were associated with TN breast cancer. A polygenic risk score (PRS) for TN breast cancer based on known breast cancer risk variants showed a 4-fold difference in risk between the highest and lowest PRS quintiles (OR = 4.03, 95% confidence interval 3.46-4.70, P = 4.8 × 10(-) (69)). This translates to an absolute risk for TN breast cancer ranging from 0.8% to 3.4%, suggesting that genetic variation may be used for TN breast cancer risk prediction.

Published
2014

19. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27

Author

Niravath, Polly, Chen, Bingshu, Chapman, Judy-Anne W., Agarwal, Sandeep K., Welschhans, Robert L., Bongartz, Tim, Kalari, Krishna R., Shepherd, Lois E., Bartlett, John, Pritchard, Kathleen, Gelmon, Karen, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Goss, Paul E., and Ingle, James N.

Published
2018
Full Text
View/download PDF

22. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk

Author

Yau, Christina, Sninsky, John, Kwok, Shirley, Wang, Alice, Degnim, Amy, Ingle, James N, Gillett, Cheryl, Tutt, Andrew, Waldman, Fred, Moore, Dan, Esserman, Laura, and Benz, Christopher C

Abstract

Abstract Introduction Outcome predictors in use today are prognostic only for hormone receptor-positive (HRpos) breast cancer. Although microarray-derived multigene predictors of hormone receptor-negative (HRneg) and/or triple negative (Tneg) breast cancer recurrence risk are emerging, to date none have been transferred to clinically suitable assay platforms (for example, RT-PCR) or validated against formalin-fixed paraffin-embedded (FFPE) HRneg/Tneg samples. Methods Multiplexed RT-PCR was used to assay two microarray-derived HRneg/Tneg prognostic signatures IR-7 and Buck-4) in a pooled FFPE collection of 139 chemotherapy-naïve HRneg breast cancers. The prognostic value of the RT-PCR measured gene signatures were evaluated as continuous and dichotomous variables, and in conditional risk models incorporating clinical parameters. An optimized five-gene index was derived by evaluating gene combinations from both signatures. Results RT-PCR measured IR-7 and Buck-4 signatures proved prognostic as continuous variables; and conditional risk modeling chose nodal status, the IR-7 signature, and tumor grade as significant predictors of distant recurrence (DR). From the Buck-4 and IR-7 signatures, an optimized five-gene (TNFRSF17, CLIC5, HLA-F, CXCL13, XCL2) predictor was generated, referred to as the Integrated Cytokine Score (ICS) based on its functional pathway linkage through interferon-γ and IL-10. Across all FFPE cases, the ICS was prognostic as either a continuous or dichotomous variable, and conditional risk modeling selected nodal status and ICS as DR predictors. Further dichotomization of node-negative/ICS-low FFPE cases identified a subset of low-grade HRneg tumors with

Published
2013

25. Table S2 from Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer

Author

Carter, Jodi M., primary, Polley, Mei-Yin C., primary, Leon-Ferre, Roberto A., primary, Sinnwell, Jason, primary, Thompson, Kevin J., primary, Wang, Xue, primary, Ma, Yaohua, primary, Zahrieh, David, primary, Kachergus, Jennifer M., primary, Solanki, Malvika, primary, Boughey, Judy C., primary, Liu, Minetta C., primary, Ingle, James N., primary, Kalari, Krishna R., primary, Couch, Fergus J., primary, Thompson, E. Aubrey, primary, and Goetz, Matthew P., primary

Published
2023
Full Text
View/download PDF

26. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

Author

Norton, Nadine, Youssef, Bahaaeldin, Hillman, David W., Nassar, Aziza, Geiger, Xochiquetzal J., Necela, Brian M., Liu, Heshan, Ruddy, Kathryn J., Polley, Mei-Yin C., Ingle, James N., Couch, Fergus J., Perez, Edith A., Liu, Minetta C., Carter, Jodi M., Leon-Ferre, Roberto A., Boughey, Judy C., Somers, Elizabeth B., Kalari, Krishna R., Visscher, Daniel W., Goetz, Matthew P., and Knutson, Keith L.

Published
2020
Full Text
View/download PDF

30. Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer

Author

Ingle, James N., Kalari, Krishna R., Momozawa, Yukihide, Kubo, Michiaki, Furukawa, Yoichi, Shepherd, Lois E., Ellis, Matthew J., Goss, Paul E., Barman, Poulami, Carlson, Erin E., Sinnwell, Jason P., Tang, Xiaojia, Goetz, Matthew P., Chen, Bingshu E., Cairns, Junmei, Weinshilboum, Richard M., and Wang, Liewei

Published
2019
Full Text
View/download PDF

32. Supplementary Figure S2 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention

Author

Ingle, James N., primary, Liu, Mohan, primary, Wickerham, D. Lawrence, primary, Schaid, Daniel J., primary, Wang, Liewei, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Costantino, Joseph P., primary, Vogel, Victor G., primary, Paik, Soonmyung, primary, Goetz, Matthew P., primary, Ames, Matthew M., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Carlson, Erin E., primary, Flockhart, David A., primary, Wolmark, Norman, primary, Nakamura, Yusuke, primary, and Weinshilboum, Richard M., primary

Published
2023
Full Text
View/download PDF

34. Data from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention

Author

Ingle, James N., primary, Liu, Mohan, primary, Wickerham, D. Lawrence, primary, Schaid, Daniel J., primary, Wang, Liewei, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Costantino, Joseph P., primary, Vogel, Victor G., primary, Paik, Soonmyung, primary, Goetz, Matthew P., primary, Ames, Matthew M., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Carlson, Erin E., primary, Flockhart, David A., primary, Wolmark, Norman, primary, Nakamura, Yusuke, primary, and Weinshilboum, Richard M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Material from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention

Author

Ingle, James N., primary, Liu, Mohan, primary, Wickerham, D. Lawrence, primary, Schaid, Daniel J., primary, Wang, Liewei, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Costantino, Joseph P., primary, Vogel, Victor G., primary, Paik, Soonmyung, primary, Goetz, Matthew P., primary, Ames, Matthew M., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Carlson, Erin E., primary, Flockhart, David A., primary, Wolmark, Norman, primary, Nakamura, Yusuke, primary, and Weinshilboum, Richard M., primary

Published
2023
Full Text
View/download PDF

37. Data from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Author

Gucalp, Ayca, primary, Tolaney, Sara, primary, Isakoff, Steven J., primary, Ingle, James N., primary, Liu, Minetta C., primary, Carey, Lisa A., primary, Blackwell, Kimberly, primary, Rugo, Hope, primary, Nabell, Lisle, primary, Forero, Andres, primary, Stearns, Vered, primary, Doane, Ashley S., primary, Danso, Michael, primary, Moynahan, Mary Ellen, primary, Momen, Lamia F., primary, Gonzalez, Joseph M., primary, Akhtar, Arooj, primary, Giri, Dilip D., primary, Patil, Sujata, primary, Feigin, Kimberly N., primary, Hudis, Clifford A., primary, and Traina, Tiffany A., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure S2 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy

Author

Ingle, James N., primary, Xie, Fang, primary, Ellis, Matthew J., primary, Goss, Paul E., primary, Shepherd, Lois E., primary, Chapman, Judith-Anne W., primary, Chen, Bingshu E., primary, Kubo, Michiaki, primary, Furukawa, Yoichi, primary, Momozawa, Yukihide, primary, Stearns, Vered, primary, Pritchard, Kathleen I., primary, Barman, Poulami, primary, Carlson, Erin E., primary, Goetz, Matthew P., primary, Weinshilboum, Richard M., primary, Kalari, Krishna R., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure from Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer

Author

Fasching, Peter A., primary, Liu, Duan, primary, Scully, Steve, primary, Ingle, James N., primary, Lyra, Paulo C., primary, Rack, Brigitte, primary, Hein, Alexander, primary, Ekici, Arif B., primary, Reis, Andre, primary, Schneeweiss, Andreas, primary, Tesch, Hans, primary, Fehm, Tanja N., primary, Heinrich, Georg, primary, Beckmann, Matthias W., primary, Ruebner, Matthias, primary, Huebner, Hanna, primary, Lambrechts, Diether, primary, Madden, Ebony, primary, Shen, Jess, primary, Romm, Jane, primary, Doheny, Kim, primary, Jenkins, Gregory D., primary, Carlson, Erin E., primary, Li, Liang, primary, Fridley, Brooke L., primary, Cunningham, Julie M., primary, Janni, Wolfgang, primary, Monteiro, Alvaro N.A., primary, Schaid, Daniel J., primary, Häberle, Lothar, primary, Weinshilboum, Richard M., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

40. Data from Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer

Author

Fasching, Peter A., primary, Liu, Duan, primary, Scully, Steve, primary, Ingle, James N., primary, Lyra, Paulo C., primary, Rack, Brigitte, primary, Hein, Alexander, primary, Ekici, Arif B., primary, Reis, Andre, primary, Schneeweiss, Andreas, primary, Tesch, Hans, primary, Fehm, Tanja N., primary, Heinrich, Georg, primary, Beckmann, Matthias W., primary, Ruebner, Matthias, primary, Huebner, Hanna, primary, Lambrechts, Diether, primary, Madden, Ebony, primary, Shen, Jess, primary, Romm, Jane, primary, Doheny, Kim, primary, Jenkins, Gregory D., primary, Carlson, Erin E., primary, Li, Liang, primary, Fridley, Brooke L., primary, Cunningham, Julie M., primary, Janni, Wolfgang, primary, Monteiro, Alvaro N.A., primary, Schaid, Daniel J., primary, Häberle, Lothar, primary, Weinshilboum, Richard M., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Author

Gucalp, Ayca, primary, Tolaney, Sara, primary, Isakoff, Steven J., primary, Ingle, James N., primary, Liu, Minetta C., primary, Carey, Lisa A., primary, Blackwell, Kimberly, primary, Rugo, Hope, primary, Nabell, Lisle, primary, Forero, Andres, primary, Stearns, Vered, primary, Doane, Ashley S., primary, Danso, Michael, primary, Moynahan, Mary Ellen, primary, Momen, Lamia F., primary, Gonzalez, Joseph M., primary, Akhtar, Arooj, primary, Giri, Dilip D., primary, Patil, Sujata, primary, Feigin, Kimberly N., primary, Hudis, Clifford A., primary, and Traina, Tiffany A., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Legend from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Author

Gucalp, Ayca, primary, Tolaney, Sara, primary, Isakoff, Steven J., primary, Ingle, James N., primary, Liu, Minetta C., primary, Carey, Lisa A., primary, Blackwell, Kimberly, primary, Rugo, Hope, primary, Nabell, Lisle, primary, Forero, Andres, primary, Stearns, Vered, primary, Doane, Ashley S., primary, Danso, Michael, primary, Moynahan, Mary Ellen, primary, Momen, Lamia F., primary, Gonzalez, Joseph M., primary, Akhtar, Arooj, primary, Giri, Dilip D., primary, Patil, Sujata, primary, Feigin, Kimberly N., primary, Hudis, Clifford A., primary, and Traina, Tiffany A., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer

Author

Wei, Lixuan, primary, Gao, Huanyao, primary, Yu, Jia, primary, Zhang, Huan, primary, Nguyen, Thanh Thanh L., primary, Gu, Yayun, primary, Passow, Marie R., primary, Carter, Jodi M., primary, Qin, Bo, primary, Boughey, Judy C., primary, Goetz, Matthew P., primary, Weinshilboum, Richard M., primary, Ingle, James N., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Data from Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer

Author

Fasching, Peter A., primary, Liu, Duan, primary, Scully, Steve, primary, Ingle, James N., primary, Lyra, Paulo C., primary, Rack, Brigitte, primary, Hein, Alexander, primary, Ekici, Arif B., primary, Reis, Andre, primary, Schneeweiss, Andreas, primary, Tesch, Hans, primary, Fehm, Tanja N., primary, Heinrich, Georg, primary, Beckmann, Matthias W., primary, Ruebner, Matthias, primary, Huebner, Hanna, primary, Lambrechts, Diether, primary, Madden, Ebony, primary, Shen, Jess, primary, Romm, Jane, primary, Doheny, Kim, primary, Jenkins, Gregory D., primary, Carlson, Erin E., primary, Li, Liang, primary, Fridley, Brooke L., primary, Cunningham, Julie M., primary, Janni, Wolfgang, primary, Monteiro, Alvaro N.A., primary, Schaid, Daniel J., primary, Häberle, Lothar, primary, Weinshilboum, Richard M., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Author

Gucalp, Ayca, primary, Tolaney, Sara, primary, Isakoff, Steven J., primary, Ingle, James N., primary, Liu, Minetta C., primary, Carey, Lisa A., primary, Blackwell, Kimberly, primary, Rugo, Hope, primary, Nabell, Lisle, primary, Forero, Andres, primary, Stearns, Vered, primary, Doane, Ashley S., primary, Danso, Michael, primary, Moynahan, Mary Ellen, primary, Momen, Lamia F., primary, Gonzalez, Joseph M., primary, Akhtar, Arooj, primary, Giri, Dilip D., primary, Patil, Sujata, primary, Feigin, Kimberly N., primary, Hudis, Clifford A., primary, and Traina, Tiffany A., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., primary, Geiger, Xochiquetzal J., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Jenkins, Robert B., primary, Riehle, Darren, primary, Chen, Beiyun, primary, McCullough, Ann E., primary, Davidson, Nancy E., primary, Martino, Silvana, primary, Sledge, George W., primary, Kaufman, Peter A., primary, Kutteh, Leila A., primary, Gralow, Julie, primary, Harris, Lyndsay N., primary, Ingle, James N., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 2 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Author

Gucalp, Ayca, primary, Tolaney, Sara, primary, Isakoff, Steven J., primary, Ingle, James N., primary, Liu, Minetta C., primary, Carey, Lisa A., primary, Blackwell, Kimberly, primary, Rugo, Hope, primary, Nabell, Lisle, primary, Forero, Andres, primary, Stearns, Vered, primary, Doane, Ashley S., primary, Danso, Michael, primary, Moynahan, Mary Ellen, primary, Momen, Lamia F., primary, Gonzalez, Joseph M., primary, Akhtar, Arooj, primary, Giri, Dilip D., primary, Patil, Sujata, primary, Feigin, Kimberly N., primary, Hudis, Clifford A., primary, and Traina, Tiffany A., primary

Published
2023
Full Text
View/download PDF

48. Data from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy

Author

Ingle, James N., primary, Xie, Fang, primary, Ellis, Matthew J., primary, Goss, Paul E., primary, Shepherd, Lois E., primary, Chapman, Judith-Anne W., primary, Chen, Bingshu E., primary, Kubo, Michiaki, primary, Furukawa, Yoichi, primary, Momozawa, Yukihide, primary, Stearns, Vered, primary, Pritchard, Kathleen I., primary, Barman, Poulami, primary, Carlson, Erin E., primary, Goetz, Matthew P., primary, Weinshilboum, Richard M., primary, Kalari, Krishna R., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Material from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy

Author

Ingle, James N., primary, Xie, Fang, primary, Ellis, Matthew J., primary, Goss, Paul E., primary, Shepherd, Lois E., primary, Chapman, Judith-Anne W., primary, Chen, Bingshu E., primary, Kubo, Michiaki, primary, Furukawa, Yoichi, primary, Momozawa, Yukihide, primary, Stearns, Vered, primary, Pritchard, Kathleen I., primary, Barman, Poulami, primary, Carlson, Erin E., primary, Goetz, Matthew P., primary, Weinshilboum, Richard M., primary, Kalari, Krishna R., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data Clean from Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α

Author

Ingle, James N., primary, Cairns, Junmei, primary, Suman, Vera J., primary, Shepherd, Lois E., primary, Fasching, Peter A., primary, Hoskin, Tanya L., primary, Singh, Ravinder J., primary, Desta, Zeruesenay, primary, Kalari, Krishna R., primary, Ellis, Matthew J., primary, Goss, Paul E., primary, Chen, Bingshu E., primary, Volz, Bernhard, primary, Barman, Poulami, primary, Carlson, Erin E., primary, Haddad, Tufia, primary, Goetz, Matthew P., primary, Goodnature, Barbara, primary, Cuellar, Matthew E., primary, Walters, Michael A., primary, Correia, Cristina, primary, Kaufmann, Scott H., primary, Weinshilboum, Richard M., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results